Pituitary adenoma: Difference between revisions

	Pituitary adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pituitary adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural history, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pituitary adenoma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pituitary adenoma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pituitary adenoma
CDC on Pituitary adenoma
Pituitary adenoma in the news
Blogs on Pituitary adenoma
Directions to Hospitals Treating Pituitary adenoma
Risk calculators and risk factors for Pituitary adenoma

Revision as of 14:41, 21 January 2012

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

@@ Line 38: / Line 38: @@
 ==References==
-# {{note|thyrotrophic}}{{note_label|thyrotrophic|1|a}} Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993)  [http://www.annals.org/cgi/content/full/119/3/236 Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata]. ''Annals of Internal Medicine'' '''119''' (3), 236-240.
 ==See Also==